Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 3SBio Inc.
A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.
A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.
Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.
US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- Decade Sunshine Limited
- Decade Sunshine Merger Sub
- Hongkong Sansheng
- Shenyang Sunshine Pharmaceutical Company Ltd
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Zhejiang Wansheng Pharmaceutical Co., Ltd
- Sirton Pharmaceuticals SpA
- Sansheng Guojian Pharmaceutical (Shanghai) Co td